18.11.2024 • News

CEFIC Re-elects Ilham Kadri as President

Ilham Kadri, CEO of Syensqo, has been re-elected as president of CEFIC, the European Chemical Industry Council, for a two-year term, effective immediately.

“It is an honor to serve this extraordinary industry at such a critical time. Together, we are proving the power of partnership, driving innovation, and tackling Europe’s greatest challenges – from climate change to industrial resilience. The world is watching Europe, and the chemical industry – ‘the mother of all industries’ – is the foundation of a sustainable and competitive future. My commitment remains firm: to support our sector’s transition while ensuring Europe remains a competitive hub for innovation, investment, and opportunity,” Kadri said.

According to CEFIC, Kadri will also take on the role of president of the International Council of Chemical Associations (ICCA) on Jan. 1, 2025, during CEFIC’s two-year mandate.

Marco Mensink, CEFIC director general, commented: “Ilham’s passion and commitment to our sector are unmatched. She has inspired a united vision within CEFIC and strengthened our relationships with Europe’s key decision-makers. Her leadership gives our sector a strong voice as we advocate for practical solutions that keep Europe competitive and sustainable.”

Ilham Kadri, CEO of Syensqo, has been re-elected as president of the European...
Ilham Kadri, CEO of Syensqo, has been re-elected as president of the European Chemical Industry Council, CEFIC | © Syensqo/CEFIC

Company

Logo:

European Chemical Industry Council - Cefic aisbl

Rue Belliard 40
1040 Brussels
Belgium

Company contact







Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read